Related references
Note: Only part of the references are listed.The Biotechnology Innovation Machine: A Source of Intelligent Biopharmaceuticals for the Pharma Industry-Mapping Biotechnology's Success
R. P. Evens et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee
Peter Arlett et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Differences Between Post-Authorization Adverse Drug Reactions of Biopharmaceuticals and Small Molecules
Hans C. Ebbers et al.
BIODRUGS (2013)
Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases
Niels S. Vermeer et al.
DRUG SAFETY (2013)
From molecule to market access: Drug regulatory science as an upcoming discipline
Christine C. Gispen-de Wied et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
The risks of risk aversion in drug regulation
Hans-Georg Eichler et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Number of Patients Studied Prior to Approval of New Medicines: A Database Analysis
Ruben G. Duijnhoven et al.
PLOS MEDICINE (2013)
Safety Learning From Drugs of the Same Class: Room for Improvement
G. Stefansdottir et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Risk Minimization Activities of Centrally Authorized Products in the EU A Descriptive Study
Inge M. Zomerdijk et al.
DRUG SAFETY (2012)
European Perspective on Risk Management and Drug Safety
J. Raine et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Efficient drug approval and monitoring must rely on sound regulatory science
Emma A. Meagher et al.
NATURE MEDICINE (2011)
European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance
Kevin V. Blake et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Risk Management Plans: are they a tool for improving drug safety?
Serena Frau et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Biopharmaceutical benchmarks 2010
Gary Walsh
NATURE BIOTECHNOLOGY (2010)
Does diabetes therapy influence the risk of cancer?
U. Smith et al.
DIABETOLOGIA (2009)
Evaluation of Post-Authorization Safety Studies in the First Cohort of EU Risk Management Plans at Time of Regulatory Approval
Thijs J. Giezen et al.
DRUG SAFETY (2009)
Safety-related regulatory actions for biologicals approved in the United States and the European Union
Thijs J. Giezen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
Hans-Georg Eichler et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies
Rakesh Dixit et al.
DRUG DISCOVERY TODAY (2007)
Treating Individuals 1 - External validity of randomised controlled trials: To whom do the results of this trial apply?'
PM Rothwell
LANCET (2005)
Bioequivalence and the immunogenicity of biopharmaceuticals
H Schellekens
NATURE REVIEWS DRUG DISCOVERY (2002)
Share Paper
